PlainRecalls
FDA Drug Low Class III Terminated

Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.

Reported: June 26, 2013 Initiated: May 31, 2013 #D-607-2013

Product Description

Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.

Reason for Recall

Failed Dissolution Specification

Details

Recalling Firm
Pfizer Inc
Units Affected
5,410 botlles
Distribution
Nationwide and Puerto Rico
Location
Peapack, NJ

Frequently Asked Questions

What product was recalled?
Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.. Recalled by Pfizer Inc. Units affected: 5,410 botlles.
Why was this product recalled?
Failed Dissolution Specification
Which agency issued this recall?
This recall was issued by the FDA Drug on June 26, 2013. Severity: Low. Recall number: D-607-2013.